NasdaqGS:ZBIOBiotechs
A Look At Zenas BioPharma (ZBIO) Valuation As Losses Widen And Going Concern Risks Emerge
Zenas BioPharma (ZBIO) is back in focus after reporting a much wider Q4 net loss alongside a fresh going concern warning, while also securing access to a sizeable multi tranche debt facility extending into 2031.
See our latest analysis for Zenas BioPharma.
The wider Q4 loss, going concern warning and new debt facility have coincided with a 34.3% 3 month share price return decline and a weaker near term trend. However, the 1 year total shareholder return of about 2.8x still stands out.
If you...